Clinical Validation of Whole Genome Sequencing for Cancer Diagnostics-Reference-Cited by-同舟云学术

Clinical Validation of Whole Genome Sequencing for Cancer Diagnostics

Published:2021-07 Issue:7 Volume:23 Page:816-833
ISSN:1525-1578
Container-title:The Journal of Molecular Diagnostics
language:en
Short-container-title:The Journal of Molecular Diagnostics

Author:

Roepman Paul^ORCID,de Bruijn Ewart^ORCID,van Lieshout Stef,Schoenmaker Lieke^ORCID,Boelens Mirjam C.,Dubbink Hendrikus J.^ORCID,Geurts-Giele Willemina R.R.,Groenendijk Floris H.^ORCID,Huibers Manon M.H.,Kranendonk Mariëtte E.G.,Roemer Margaretha G.M.,Samsom Kris G.^ORCID,Steehouwer Marloes,de Leng Wendy W.J.,Hoischen Alexander,Ylstra Bauke^ORCID,Monkhorst Kim^ORCID,van der Hoeven Jacobus J.M.,Cuppen Edwin

Publisher

Elsevier BV

Subject

Molecular Medicine,Pathology and Forensic Medicine

Reference41 articles.

1. Implementing genome-driven oncology;Hyman;Cell,2017

2. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group;Mosele;Ann Oncol,2020

3. The Cancer Genome Atlas Pan-Cancer analysis project;Weinstein;Nat Genet,2013

4. Pan-cancer whole-genome analyses of metastatic solid tumours;Priestley;Nature,2019

5. Opportunities, resources, and techniques for implementing genomics in clinical care;Manolio;Lancet,2019

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Transcriptome-based classification to predict FOLFIRINOX response in a real-world metastatic pancreatic cancer cohort;Translational Research;2024-11

2. Opportunities and Challenges of Small Molecule Inhibitors in Glioblastoma Treatment: Lessons Learned from Clinical Trials;Cancers;2024-08-29

3. The evolution of precision oncology: The ongoing impact of the Drug Rediscovery Protocol (DRUP);Acta Oncologica;2024-05-23

4. Characterization of discordance between mismatch repair deficiency and microsatellite instability testing may prevent inappropriate treatment with immunotherapy;The Journal of Pathology;2024-05-15

5. Trastuzumab plus pertuzumab for HER2-amplified advanced colorectal cancer: Results from the drug rediscovery protocol (DRUP);European Journal of Cancer;2024-05